Nov 13, 2019 / 04:45PM GMT
Evan David Seigerman - Crédit Suisse AG - Research Division - VP & Senior Equity Research Analyst
Good morning. My name is Evan Seigerman, and I'm the senior large cap biotechnology analyst here at Crédit Suisse. And welcome to the second day of our Global Healthcare Conference. And today, right now, we have Moderna. And from Moderna, we have Lorence Kim, the CFO. Thank you for joining us.
Lorence H. Kim - Moderna, Inc. - CFO & Treasurer
Thanks for having us.
Evan David Seigerman - Crédit Suisse AG - Research Division - VP & Senior Equity Research Analyst
So I guess before we get started and jumping into the Q&A, can you give us an overview of where Moderna is in terms of development of your various products and kind of most recent kind of investor update?
Lorence H. Kim - Moderna, Inc. - CFO & Treasurer
Sure. We are -- we've been focused on developing messenger RNA as a technology now for about 8
Moderna Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot